Patents by Inventor Claus Claussen

Claus Claussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090117184
    Abstract: Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17?-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral contraception. The possibility is provided of improving the prophylaxis for lactose intolerance concerning a possibly contributing factor and also in regard to the costly examinations for lactose intolerance. The invention is also suitable for long-term use.
    Type: Application
    Filed: October 27, 2008
    Publication date: May 7, 2009
    Inventors: Sabine Fricke, Manuela Pfeifer, Claus Claussen, Ralf Ladwig, Beate Buerglen
  • Publication number: 20090117183
    Abstract: The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17?-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo.
    Type: Application
    Filed: October 27, 2008
    Publication date: May 7, 2009
    Inventors: Sabine Fricke, Manuela Pfeifer, Claus Claussen, Ralf Ladwig, Beate Buerglen
  • Publication number: 20080268048
    Abstract: The pharmaceutical composition for oral contraception and for reducing the risk of congenital abnormalities contains, in a daily dosage unit, 2.0 mg or 1.5 mg of 17?-cyanomethyl-17?-hydroxyoestra-4,9-dien-3-one (dienogest), 0.015 mg of 17?-ethynyloestradiol (ethynyloestradiol), and (6S)-5-methyl-tetrahydrofolate, preferably as the calcium salt of (6S)-5-methyltetrahydrofolic acid (metafolin), together with one or more pharmaceutically acceptable auxiliaries/carriers. A kit for oral contraception contains 21 daily dosage units of the pharmaceutical composition and 7 daily dosage units solely containing (6S)-5-methyltetrahydrofolate, preferably in the form of metafolin.
    Type: Application
    Filed: July 3, 2007
    Publication date: October 30, 2008
    Inventor: Claus Claussen
  • Publication number: 20060183725
    Abstract: The pharmaceutical preparation for oral contraception has 28 daily dosage units, of which at least 21 daily dosage units each contain from 1.5 mg to 2 mg of dienogest and from 0.015 mg to 0.02 mg of ethinyl estradiol together in a pharmaceutically acceptable carrier. Seven or fewer daily dosage units contain no effective ingredient. Each daily dosage unit can be a film tablet for oral administration, which has a tablet core and film coating on the tablet core. At least 30% of the dienogest is released from the tablet core preferably in a delayed manner after more than 30 minutes, while at least 70% of the dienogest and ethinyl estradiol are released from the film coating preferably in 30 minutes, as determined by a standard dissolution test.
    Type: Application
    Filed: February 9, 2006
    Publication date: August 17, 2006
    Inventors: Thomas Graeser, Claus Claussen